Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

March 1, 2025

Study Completion Date

March 31, 2026

Conditions

Colorectal Cancer Metastatic

Interventions

DRUG

Adebrelimab

This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 1200mg, administered every 3 Weeks (Q3W).

DRUG

Oxaliplatin

130 mg/m2, ivgtt, d1, Q3W

DRUG

Capecitabine

1000mg/m2, po, bid, d1-14, Q3W Maintenance therapy: 1250mg/m2, po, bid, d1-14, Q3W

DRUG

Bevacizumab

7.5mg/kg，ivgtt, d1, Q3W

Trial Locations (1)

RECRUITING

The Fourth Affiliated Hospital Zhejiang University School of Medicine, Jinhua

All Listed Sponsors

lead

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

OTHER